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Abstract
Summary The WHO fracture risk assessment (FRAX) and
Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tools can both be used to determine an individual’s 10-year risk of osteoporotic fracture. However, these
tools differ in their risk calculation. For participants <65 years
with a wrist fracture, FRAX provides a lower fracture risk
estimate than CAROC resulting in fewer decisions to initiate
therapy.
Purpose The purpose of the current report is to compare fracture risk prediction rates using the CAROC and the FRAX®
tools.
Methods Individuals ≥50 years with a distal radius fracture
resulting from a fall from standing height or less were recruited from a single orthopedic clinic. Participants underwent a
DXA scan of their lumbar spine and hip. Femoral neck (FN)
bone mineral density (BMD) and fracture risk factors were
used to determine each participant’s 10-year fracture risk
using both fracture risk assessment tools. Participants were

categorized as low (<10 %), moderate (10–20 %), or high
(>20 %) risk. Stratified by age (<65 years, >65 years), the
proportion of participants in each category was compared between the tools.
Results Analyses included 60 participants (mean age 65.7±
9.6 years). In those <65 years (n=26), the proportion of individuals at low, moderate, and high risk differed between the
FRAX and CAROC tools (p<0.0001). FRAX categorized
69 % as low (CAROC 0 %) and 3 % as high (CAROC
12 %) risk. For individuals >65 years, almost all were at least
at moderate risk (FRAX 79 %, CAROC 53 %), but fewer were
at high risk using FRAX (18 vs. 47 %, p<0.0003).
Conclusion For participants <65 years with a wrist fracture,
FRAX provides a lower estimate of 10-year fracture risk than
CAROC resulting in fewer decisions to initiate therapy. However, almost all participants >65 years were at moderate or
high risk under both FRAX and CAROC and should at least
be considered for pharmacotherapy.
Keywords Osteoporosis . Distal radius fracture . Clinical
practice guidelines . Fracture risk . FRAX
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Following publication of the 2010 clinical practice guidelines
(CPG) for the diagnosis and management of osteoporosis in
Canada [1], Osteoporosis Canada emphasized the need to
evaluate future fracture risk in all older individuals who experience a major Bfragility^ fracture typically associated with
osteoporosis (i.e., hip, clinical or morphometric vertebra, pelvis, and forearm or proximal humerus).
In Canada, two fracture risk prediction tools exist to determine an individual’s 10-year risk of osteoporotic fracture. The
Canadian Association of Radiologists and Osteoporosis
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Canada (CAROC) tool stratifies women and men >50 years
into three categories of osteoporotic fracture risk: low
(<10 %), moderate (10–20 %), and high (>20 %) [2]. Baseline
risk is assessed using age, sex, and femoral neck T-score. The
presence of a prior fragility fracture after age 40 [3] or recent
prolonged use of systemic glucocorticoids increases fracture
risk into the next highest category independent of bone mineral density (BMD). The World Health Organization Fracture
Risk Assessment (FRAX©) tool uses additional risk factors
over and above those used in CAROC (e.g., parental history
of hip fracture) [4]. Lumbar spine BMD is not considered in
either tool.
Overall, observed fracture rates for Canadians are in close
agreement to the rates predicted by both tools [5]. Osteoporosis
Canada recommended the CAROC tool be adopted in preference to FRAX based on its relative simplicity and wider national availability. The CPG recommend that all high-risk individuals be offered pharmacotherapy, while those at moderate
risk be regarded with some circumspection before initiating
therapy and only considered if there are other risk factors and
in accordance with patient preference. This is important in primary practice considering wrist fractures comprise 26–46 % of
all observed skeletal fractures [6–11] and are the most common
fragility fracture seen in fracture clinics in this age group.
Although a fragility fracture increases the risk for future
fractures, there is evidence that wrist fractures are associated
with significantly lower re-fracture rates in the following 5–
10 years than is observed following other Bosteoporotic^ fractures (e.g., vertebra, hip, or proximal humerus), especially in
younger individuals with non-osteoporotic BMD values [12].
Here, we compare the results of applying the CAROC and
FRAX tools to 60 participants presenting to a single orthopedic clinic after a wrist fracture to assess differences in treatment directives resulting from their respective risk
stratification.
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information and information about fragility fractures after age
40 years. BMD testing was performed on a Lunar Prodigy
Advance system (GE Healthcare, with a precision of ±0.01 g/
cm2 at the femoral neck). Under current guidelines, only the
femoral neck T-score was used for risk categorization.
Osteophytic artifact due to degenerative disk disease, facet joint
arthropathy, etc. formed part of the lumbar spine report structure if visually apparent on the densitometer images. All BMD
reports were read by one trained clinician (ABH).
The purpose of the current report is to compare and contrast
the risk categorization between the CAROC and FRAX tools
when applied to all 60 participants. The Canadian reference
population was used for the FRAX calculation. Each participant’s fracture risk was assessed using each tool. Incomplete
information on parental history of hip fracture collected at study
entry might have systematically underestimated future fracture
risk calculated for FRAX. We address the question of whether
the use of either tool in primary practice will lead to the same or
discordant therapeutic decisions. This study was approved by
the Institutional Review Board for Research involving Human
Subjects at Western University and the Hamilton Integrated
Research Ethics Board at McMaster University.

Analyses
Baseline demographic data are reported as means (SD). Statistical differences between younger and older participants
were defined by Student’s t test. Categorical differences in
the proportion of participants assigned to the three risk categories between the CAROC and FRAX systems were evaluated by testing for marginal homogeneity using the
Bhapkar test.

Results
Methods
Individuals ≥50 years old presenting with a fragility fracture
[13] of the distal forearm were recruited from the orthopedic
clinic at St. Joseph’s Health Care, London, Ontario. Individuals
previously diagnosed with osteoporosis by self-report or currently taking osteoporosis medication were excluded. Given
that the study’s primary goal was to observe the response of
family physicians to the patients’ fracture risk reported by
CAROC or FRAX (prescribed treatment or not), participants
who had not previously been diagnosed with osteoporosis or
who had not been treated for osteoporosis were the target study
population [14]. Subjects consented to enrolment in a clinical
study designed to monitor treatment outcomes from their family physicians and were provided with BMD assessments. A
trained research assistant collected baseline demographic

Baseline demographic data are shown for all participants stratified by age (Table 1). For all 60 participants, the mean age
was 65.7±9.6 years. Almost half (n=26 [43 %]) were younger
than 65 years, <20 % were men and 18 (30 %) recalled a
parental history of either osteoporosis or fracture. Few were
currently taking glucocorticoids or undergoing treatment for
rheumatoid arthritis.
Femoral neck T-scores were not lower than expected for
the age- and sex-matched reference population (Table 1).
Femoral neck BMD was significantly (p<0.001) higher in
participants <65 years compared with those >65 years (Tscore −1.1±0.9 vs. −1.5±0.6). Lumbar spine BMD was similar between groups, and T-scores were slightly higher than
those at the femoral neck. This is likely explained by a high
prevalence of measurement artifact due to osteophytic disease
(nearly 80 % of cohort).
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Table 1 Baseline characteristics
for all participants and stratified
by age

p valuea

All

<65 years

>65 years

Number of subjects

60

26

34

Age, years

65.7±9.6

56.7±4.6

72.5±6.0

Female/male

49/11

21/5

28/6

Fracture prior to current wrist fracture

2

2

0

Family history of osteoporosis

18

9

9

Current steroid therapy

2

0

2

Rheumatoid arthritis

3

1

2

Femoral neck BMD, g/cm2

0.85±0.12

0.91±0.16

0.81±0.06

Femoral neck T-score

−1.2±0.9

−0.8±1.2

−1.5±0.6

0.034

Lumbar spine BMD, L2–L4, g/cm2

1.15±0.24

1.12±0.24

1.17±0.25

NS

Lumbar spine T-score

−0.5±2.0

−0.7±1.9

−0.3±2.0

NS

Femoral neck BMD, g/cm2

0.87±0.10

0.92±0.11

0.82±0.06

0.003

Femoral neck T-score

−1.0±0.9

−0.5±0.9

−1.4±0.7

0.004

Lumbar spine BMD, L2–L4, g/cm2

1.13±0.15

1.18±0.18

1.08±0.11

NS

Lumbar spine T-score

−0.6±1.3

−0.2±1.5

−0.98±1.0

NS

FRAX, 10-year probability of future fragility fracture, %

12.5±5.1

9.1±4.0

15.2±4.3

<0.001

<0.001

FRAX patients
0.022

CAROC patients

NS not significant
a

p values represent comparisons between <65 years and >65 years

In applying the FRAX tool to all participants, the mean 10year probability of future major osteoporotic fracture was 12.5
±5.1 %. Fracture probability was significantly lower in those
<65 years than in those >65 years (9.1±4.0 vs. 15.2±4.3 %,
p<0.001) (Table 1).
Table 2 demonstrates the respective differences in risk category by the CAROC and FRAX systems based upon the
proportion of participants at low, moderate, and high risk.
Table 2 Fracture risk category for all participants and those younger
and older than 65 years using FRAX and CAROC

All subjects, n=60a
Low
Moderate
High
Age <65 years, n=26a
Low
Moderate
High
Age>65 years, n=34a
Low
Moderate
High

FRAX

CAROC

N (%)
19 (32)
34 (57)
7 (12)

N (%)
0
41 (68)
19 (32)

18 (69)
7 (27)
1 (4)

0
23 (88)
3 (12)

1 (3)
27 (79)
6 (18)

0
18 (53)
16 (47)

The proportion of subjects assigned to each of the three risk categories is
significantly different between the FRAX and CAROC tools, both for all
subjects, for those ≤65 years and for those >65 years (p<0.001)
a

p<0.001 for difference in risk categorization

Using FRAX, 19 (32 %) of all participants were at low risk
while only 7 (12 %) were at high risk. Differences in the
proportions of participants categorized according to their fracture risk were significant (p≤0.001) whether analyzed for all
ages combined, in younger or older participants.
In the 26 participants <65 years, FRAX categorized 18
(69 %) as low risk and only 1 (3 %) as high risk. None of
the participants <65 years was low risk by CAROC due to an
automatic increase of one risk category based upon the presence of a prior fragility wrist fracture. CAROC categorized 23
(88 %) as moderate and 3 (12 %) as high risk.
For participants >65 years, almost all were at least at moderate risk (FRAX 79 %, CAROC 53 %), but FRAX categorized fewer participants as high risk (18 vs. 47 %).

Discussion
It is clear that the two fracture risk assessment tools available
to Canadian physicians provide significantly different risk estimates for adults presenting with a wrist fracture, particularly
in those <65 years. In the current study, more than half of wrist
fractures occurred in individuals <65 years of age in whom
average femoral neck T-scores were considerably higher than
−2.5 and typically average for age. For this important group of
individuals, the operating characteristics of FRAX differ significantly from CAROC. The FRAX algorithm provides a
continuous assessment of future fracture risk and includes
prevalent fragility fractures within the statistical modeling.
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Using FRAX, participants with prior fractures may still be at
low risk of future fractures. On the other hand, CAROC
does not predict a low risk in anyone presenting with a
fragility fracture. Even if the measured BMD indicates excellent bone mass, the baseline low risk will be increased to
moderate risk by the prevalent fracture. Thus, FRAX categorized two thirds of those <65 years as low risk—a group
for whom the 2010 CPG advise no consideration for pharmacological intervention. Only 1 patient was high risk and
thus a candidate for initiating therapy. The picture is very
different when CAROC is used. All participants <65 years
would at least be considered for pharmacotherapy, as they
were at moderate (88 %) or high (12 %) risk.
The situation is less disparate in older individuals. In
those >65 years, two and a half times as many were categorized as high risk by the CAROC tool, compared with
FRAX, and would therefore be advised to initiate pharmacotherapy. However, all participants otherwise characterized
as moderate risk by CAROC would also be similarly characterized by FRAX; again, these individuals should at least
be considered for pharmacotherapy, depending on other risk
factors and patient preferences.
It is now generally accepted that any prevalent fragility fracture is a marker of increased fracture risk. This was first clearly
demonstrated for clinical and/or morphometric vertebral fractures [15, 16], but has been confirmed for all fragility fractures
in epidemiological cohort studies and in large randomized controlled trials of new osteoporosis therapies in which individuals
specifically at risk for fragility fractures were studied [3]. The
risk of subsequent fracture after wrist fracture may, in part, be
age- and gender-dependent, as demonstrated by [17] et al., with
women <70 years of age having been shown to have no increase in subsequent hip fracture risk.
Hodsman et al. evaluated the risk of refracture in women
presenting with a primary wrist fracture. In this study, the
observed 10-year refracture rate across all ages (≥50 years)
was 14.2 % (95 % CI, 11.9–16.5), consistently in the moderate risk category. This rate was significantly lower for individuals <65 years (compared to those >65 years) and for
individuals with T-scores >−2.5 [12]. Thus, some individuals
are clearly at low risk of refracturing after a primary wrist
fracture and would not be advised to initiate treatment under
the current CPG. This is important considering wrist fractures
comprise up to 50 % of the clinical fragility fracture burden
within the population.
Many individuals view their wrist fracture as an unfortunate result of a traumatic fall and are reluctant to have their
accident Bmedicalised^ to the point of starting an osteoporotic
treatment. The FRAX tool allows the practitioner a more flexible environment in which to arrive at an informed decision
with the patient around the initiation of therapy. FRAX may
be the preferred tool as it will be more conservative in
selecting individuals for pharmacotherapy.
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This argument may be especially relevant for individuals
<65 years presenting with a wrist fracture. Provided the wrist
fracture is the first Bfragility^ fracture in adult life, and after
confirming there is no evidence for morphometric vertebral
compression fractures, the physician may consider such individuals at low risk for refracture. Regardless, planned surveillance with interval BMD monitoring should be the standard of
care for all individuals with a wrist fracture in whom a conservative approach is adopted.

Limitations
Results from this small study clearly demonstrate that the
FRAX and CAROC fracture risk prediction tools provide different estimates of the likelihood of future Bosteoporotic^ fractures following a wrist fracture, particularly in individuals
<65 years. However, this requires validation by applying each
tool prospectively to BMD measurements obtained from
population-based studies in which future fractures are documented in those presenting with primary wrist fractures.

Conclusions
For individuals <65 years who have sustained a wrist fracture,
the FRAX tool provides a lower 10-year fracture risk estimate
than CAROC and appropriately results in fewer decisions to
initiate therapy. However, almost all individuals >65 years are
at moderate or high risk under both FRAX and CAROC and
should at least be considered for pharmacotherapy.
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